NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
134.6 USD | +0.37% |
|
-0.65% | +2.13% |
NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
1st Jan change | Capi. | |
---|---|---|
+2.13% | 13.54B | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+119.39% | 10.96B |